Category Archives: Personalia

Natalia Nowak joins CVC Credit Partners’ European Private Debt team

Natalia joins as managing director focusing on opportunities in the DACH region and other European investments

CVC Credit Partners announced today that Natalia Nowak has joined the firm as a Managing Director in the European Private Debt team, focusing primarily on opportunities in the DACH region and other European investments. Natalia will report to Neale Broadhead, Managing Director and Portfolio Manager.

Natalia joined CVC Credit Partners from ESO Capital, where she was a Managing Director in the private debt and special situations fund. She focused on sourcing, structuring and executing bespoke financings for European SMEs. Prior to joining ESO Capital, Natalia worked at Arrowgrass and Cerberus Capital, where she worked on deals in private equity, special situations and distressed debt. Natalia began her career at Goldman Sachs in the German M&A Corporate Finance Group and is a graduate of the European Business School and Harvard Business School where she received her MBA.

Natalia Nowak said: “I am very excited to be joining CVC at such an interesting time in the private debt space, particularly as the European market continues to grow. I really look forward to working with Tom Newberry and the wider Private Debt team to build out our presence in the DACH markets and source interesting investment opportunities across Europe.”

Tom Newberry, Partner and Global Head of Private Debt at CVC Credit Partners, added: “We are delighted to welcome Natalia to CVC’s Private Debt team. Her wealth of experience, particularly in the DACH region, will be invaluable to us as we continue to look for opportunities to support high quality, medium-sized businesses across Europe and the US.”

Categories: Personalia

Tags:

Appointments at Tesi

Tesi

Henri Hakamo has been appointed as Tesi’s Chief Digital Officer (CDO), Mikael Niemi as Investment Director and Elisa Lehmusniemi as Executive Assistant. Juha Lehtola returns to Tesi’s Venture Capital team as Director.

Henri Hakamo, M.Sc. (Econ), (32), has been appointed Chief Digital Officer with effect from 3 September 2018. CDO is a new position in Tesi. He will be a member of the Management Team and report to CEO Jan Sasse. Henri transfers to Tesi from a managerial position in BearingPoint, where he was in charge of Digital & Strategy consulting in the Middle East.

Juha Lehtola, M.Sc. (Technology), (42), returns to head Tesi’s Venture Capital team as Director. As a member of the Management Team, he will report to CEO Jan Sasse. Over the last two years. Juha was an Investment Manager in the European Investment Fund, specialising in investments in European venture capital funds.

Mikael Niemi, M.Sc. (Econ), M.Sc. (Technology), (38), has been appointed Investment Director, Growth & Industrial Investments with effect from 1 August 2018. Mikael transfers to Tesi from Armada Mezzanine Capital, in which he was a Partner.

Elisa Lehmusniemi, M.Sc. (Econ), (37), has been appointed Executive Assistant as from 13 August 2018. Elisa transfers to Tesi from Borenius Attorneys LLP, where she was an executive assistant.

“Tesi’s goal is twofold: to help Finnish companies grow and internationalise; and to develop Finland’s venture capital and private equity market. Our staff are in a key position in working towards this goal. I’m very pleased that we’ve succeeded in supplementing our teams with professionals who have valuable, broad-ranging experience in the fields of investment and corporate development,” say CEO Jan Sasse.

Further information:
Jan Sasse, CEO, tel: +358 40 861 9151

Tesi (Finnish Industry Investment Ltd) is a venture capital and private equity company that invests profitably and responsibly, creating value from day one. Our investments under management total 1.2 billion euros and we have over 700 companies in portfolio, either directly or through funds. We help Finland to the next level of growth and internationalisation. Follow our success stories: www.tesi.fi / dtg.tesi.fi / @TesiFII.

Categories: Personalia

TA Associates Announces New Hires in Menlo Park

TA associates

BOSTON and MENLO PARK – TA Associates, a leading global growth private equity firm, today announced the recent hiring of Calen Angert and Nicholas Leppla, who have rejoined the firm as Vice Presidents in its Menlo Park office.

“We are thrilled to welcome back Calen and Nick to the firm,” said Brian J. Conway, Chairman and Managing Partner at TA Associates. “As Associates, both proved to be valuable contributors to TA on several fronts, particularly in our deal sourcing and due diligence efforts. We look forward to Calen and Nick’s contributions as we continue to seek investments in profitable growth companies and partner with the management teams of our portfolio companies to create further value.”

Calen Angert focuses on investments in healthcare companies across North America. Prior to attending graduate school, he served as an Associate in the Boston office of TA Associates. Mr. Angert previously served as an Analyst in the Healthcare Investment Banking Group at Morgan Stanley. He received a BSBA, magna cum laude, in Finance from the McDonough School of Business at Georgetown University and an MBA from the Stanford Graduate School of Business.

Nicholas Leppla focuses on investments in technology companies across North America. Prior to attending graduate school, he served as an Associate in the Menlo Park office of TA Associates. Mr. Leppla previously served as the Chief of Staff of AVG Technologies, a former TA portfolio company, and as an Analyst in the Technology, Media and Telecommunications Investment Banking Group at J.P. Morgan. He received a BA in Economics and Engineering Sciences (Environmental) from Yale University and an MBA from the Stanford Graduate School of Business.

About TA Associates
Now in its 50th year, TA Associates is one of the largest and most experienced global growth private equity firms. Focused on five target industries – technology, healthcare, financial services, consumer and business services – TA invests in profitable, growing companies with opportunities for sustained growth, and has invested in nearly 500 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in growth companies. TA has raised $24 billion in capital since its founding in 1968 and is committing to new investments at the pace of $1.5 to $2 billion per year. The firm’s more than 85 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA Associates can be found at www.ta.com.

 

Categories: Personalia

Tags:

AURELIUS Group to expand its management team

Aurelius Capital

  • Donatus Albrecht to look after the group-wide M&A strategy
  • Matthias Täubl newly appointed to the Executive Board with responsibility for operations

Munich, July 17, 2018 – AURELIUS Equity Opportunities SE & Co. KGaA (ISIN DE000A0JK2A8) is announcing changes to its Executive Board today. From August 1, 2018, Donatus Albrecht will look after the group-wide M&A strategy of all business areas of the AURELIUS Group and will step down from the Executive Board of the listed AURELIUS Equity Opportunities SE & Co. KGaA. Matthias Täubl, who has already been with AURELIUS since 2008, will join the Executive Board with responsibility for operations at the same time.

These personnel changes are in response to the significant increase in the size of the AURELIUS Group in recent years, which now has operations as an investment group across Europe. Since it was founded, AURELIUS has progressed from being a local turnaround investor to a pan-European multi-asset manager. AURELIUS Equity Opportunities is the publicly traded investment arm with a focus on the acquisitions of companies in transitional or exceptional situations. The AURELIUS Group also operates in the Growth Capital and Debt Opportunities business fields.

Donatus Albrecht to look after the group-wide M&A strategy

Donatus Albrecht will head up the acquisitions and sales for all of the Group’s business areas in the future. Before now, Donatus Albrecht was a board member at AURELIUS Equity Opportunities, where he was responsible for the M&A activities. He has managed a total of more than 70 corporate transactions to date in his career.

Matthias Täubl newly appointed to the Executive Board with responsibility for operations

Matthias Täubl will join the Executive Board of AURELIUS Equity Opportunities, where he will be responsible for the realignment of portfolio companies. Matthias Täubl has already held various positions on the AURELIUS Task Force since 2008, responsible among other things for the very successful realignment of the Getronics group, which was sold in 2017 as the largest exit in the company’s history to date. He studied International Business Relations at the University of Applied Sciences in Eisenstadt in Austria and at Helsinki Business Polytechnic in Finland.

Categories: Personalia

Tags:

The Carlyle Group Names Minoru Koshibe as Senior Advisor

Carlyle

Industry Veteran Brings Abundant Insights and Broad Network to Support Investments and Portfolio Management

Tokyo, Japan, July 12, 2018 – Global alternative asset manager The Carlyle Group (NASDAQ: CG) today announced that Minoru Koshibe, former Executive Vice President of Mitsui Chemicals, Inc., has been appointed as a Senior Advisor to Carlyle Japan advisory team.

Mr. Koshibe will advise the Carlyle team on the business environment and key trends in sectors such as the chemicals industry. He will also support the management teams of Carlyle’s portfolio companies regarding corporate governance, operations, branding and growth strategies.

Carlyle currently has a global team of more than 40 Operating Executives, Senior Advisors and Operating Advisors with an average of more than 30 years’ experience as executives and leaders at top-tier companies. They support Carlyle’s sourcing and value creation activities across a broad range of industries. In Japan, Carlyle now has five Senior Advisors with the addition of Mr. Koshibe. Others are Mr. Tamotsu Adachi, former Co-Representative of Carlyle Japan and current Representative Director, President and CEO of Benesse Holdings, Inc.; Mr. Yukio Kubota, former President of Sony Ericsson Mobile Communications Japan, Inc.; Mr. Yasuo Nishiguchi, former President and CEO of Kyocera Corporation; and Mr. Yutaka Nishimura, former President and Regional CEO of Richemont Japan Ltd.

Kazuhiro Yamada, Managing Director and Representative of Carlyle Japan LLC, said, “I would like to sincerely welcome Mr. Koshibe to our team. During his 40-year career at Mitsui Chemicals and its predecessor, Mitsui Toatsu, Mr. Koshibe has developed significant expertise spanning from on-the-field manufacturing/production to research and process development, and extending to corporate planning, sales and business development (M&A and partnerships/alliances). With his appointment, the Carlyle team in Japan will have a strong team of five Senior Advisors, helping us to source new deals and create even more value in the companies we invest in.”

Mr. Koshibe said, “I am honored to be part of Carlyle’s Senior Advisor team. I look forward to working closely with the Carlyle Japan team to achieve further success by leveraging my experience and industry knowledge. I also hope to support the value creation of Carlyle’s portfolio companies, and hence contribute to the revitalization of the overall Japanese economy.”

Mr. Koshibe joined Mitsui Toatsu Chemicals Co., Ltd. (currently Mitsui Chemicals, Inc.) in 1978 and held positions including Corporate Planning, Executive Officer, and Planning and Development Director for the Material Business Department, and Managing Executive Officer. In 2013, he was appointed Representative Director and Executive Vice President.

Mr. Koshibe has engaged in numerous domestic and cross-border mergers and acquisitions, helping to expand Mitsui Chemical’s businesses especially in the fields of healthcare and agrichemicals, and adding new products such as electronic glasses. He led the establishment of the company’s mid-term business plan and business portfolio restructuring, including new business partnerships, delistings and demergers. Currently, Mr. Koshibe serves as Senior Councilor for Mitsui Chemicals, Inc., Executive Advisor for Mitsui & Co., Ltd., and Consultant for LOTTE Corporation. He is also actively involved in a variety of industrial organizations, serving as, for instance, the Director for “Kokuryoku Baizou Juku” (a General Incorporated Association), Advisor for “Furusato TV” (a Nonprofit Organization), Representative Facilitator for Thomson Reuters Salon, and Supporter of Monozukuri Nadeshiko.

Mr. Koshibe earned his B.A. and M.A. from Osaka University’s School of Science.

Categories: Personalia

Tags:

Breath Therapeutics Appoints Noreen Roth Henig, M.D. as Chief Medical Officer

GIlde Healthcare

Breath Therapeutics Appoints Noreen Roth Henig, M.D. as Chief Medical Officer

– Dr. Henig adds leadership and development expertise in pulmonary disease, inhaled therapies, and orphan disease to the executive management team

– Breath Therapeutics is targeting Bronchiolitis Obliterans with their first molecule, a Phase 3 ready asset

Munich, Frankfurt, Boston — Breath Therapeutics B.V. (Breath), a private company developing advanced drug-aerosol therapeutics in pulmonary orphan indications, announced today the appointment of Noreen Roth Henig, M.D. as Chief Medical Officer. Dr. Henig joins the executive management team and will lead Breath’s clinical development activities.

Dr. Henig brings to Breath more than 20 years of clinical and development leadership experience at emerging and leading biopharmaceutical companies, complemented by extensive medical experience in pulmonary and transplant medicine. Her expertise substantially strengthens BOSTON, the lead development program of inhaled L-CsA (Liposomal Cyclosporine A), for the treatment of Bronchiolitis Obliterans (BO), a lethal orphan respiratory disease. Breath’s pipeline of inhaled therapeutics is targeting severe respiratory diseases with high unmet medical need.

“Noreen´s background in advanced lung disease and lung transplant, her senior drug development expertise, and her strong strategic corporate thinking is an outstanding combination and perfectly complements the Breath management team“, said Dr. Jens Stegemann, Chief Executive Officer of Breath Therapeutics.

Noreen Henig stated: “I am looking forward to joining the Breath Therapeutics team and to growing the young company. This is a unique opportunity to develop a promising Phase 3 ready asset for a true unmet medical need“.

Prior to joining Breath, Dr. Henig was CMO of ProQR Therapeutics, where she oversaw all preclinical and clinical development of candidate molecules and was also responsible for patient safety, data transparency, medical ethics and governance. She successfully led the young biotech company through organic growth and was instrumental in raising a pre-IPO series and a successful NASDAQ IPO for the then preclinical stage company. Previously, Dr. Henig served as Senior Director, Global Medical Affairs, Respiratory and PAH of Gilead Sciences, where she designed and executed clinical trials, up to Phase 4. In particular, she provided medical support to two therapies indicated for severe pulmonary disease. Throughout her career, Dr. Henig has held several senior academic positions related to respiratory diseases and lung transplant at the California Pacific Medical Center and the Stanford University School of Medicine. She earned her M.D. with Distinction in Immunology from the Albert Einstein College of Medicine, completed training in Internal Medicine at UCSF and Pulmonary and Critical Care Medicine at University of Washington, Seattle.

 

About Bronchiolitis Obliterans (BO)

Bronchiolitis Obliterans (BO) is a severe progressive orphan disease of the bronchioles of the lung that leads to death from respiratory failure. BO is the leading cause of loss of transplanted lungs. Of more than 25 000 people currently living with a lung transplant, approximately half will die within the next five years, mainly related to BO. BO also occurs in patients following allogeneic hematopoietic stem cell transplant, autoimmune disease and some environmental exposures.

About Breath Therapeutics

Breath is a clinical stage biopharmaceutical company specializing in advanced and first-in-class inhalation therapies for severe respiratory diseases with high unmet medical need. For its clinical development, the Company is using new proprietary drug formulations optimized for inhaled administration with exclusively licensed, high performance nebulizers. Breath is focusing on integrated therapy solutions in the interaction between diagnostics, therapeutics and eHealth therapy monitoring.

Breath´s lead development program BOSTON is addressing the treatment of BO with a proprietary formulation of liposomal cyclosporine for inhalation. With proceeds from a USD 46 million Series A financing by top-tier European investors Sofinnova, Gimv and Gilde Healthcare, the Company is currently initiating Phase 3 studies in the US and Europe. PARI Pharma, a worldwide leading nebulizer company, is a strategic development partner and licensor for the eFlow® nebulizer technology for Breath’s BOSTON program.

Breath Therapeutics is Germany and US based with offices in Frankfurt, Munich and Boston.

For more information, please visit www.breath-therapeutics.com

Contact:

Breath Therapeutics B.V.
Dr. Jens Stegemann, CEO
Email: contact@breath-therapeutics.com

Media inquiries:

MC Services AG
Dr. Claudia Gutjahr-Loeser, Managing Director
Tel. +49 89 210 228–0
Email: breath-therapeutics@mc-services.eu

 

Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($1 billion) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcare services across Europe and the US.

 

Categories: Personalia

Tags:

Industrifonden Life Science recruits Bita Sehat as Investment Manager

IndustrieFonden

Industrifonden strengthens its Life Science investment team through the recruitment of Dr. Bita Sehat as Investment Manager. Bita brings over 10 years of scientific expertise in oncology as well as corporate experience from Europe and North America.

Prior to joining Industrifonden, Bita Sehat held the position of Head of Business Development and Strategic Partnerships for Battat Inc., a consumer goods company. Her previous experience also includes positions in the health care team at Caisse de dépôt et placement du Québec, the Canadian investment fund, and Foster Rosenblatt Consulting, a forecasting and valuation firm in the pharmaceutical area.

Therapeutics remain the core of our business. The pharmaceutical industry is in the midst of an innovation leap, spearheaded by clinically meaningful novel therapies in areas such as oncology and immunology. Bita’s deep understanding for oncology combined with her North American business experience will be a great addition to our team, says Nina Rawal, Head of Life Science at Industrifonden.

Bita Sehat holds a Master of Science in Biomedicine and a Ph.D. in molecular oncology, both from Karolinska Institute. Her scientific experience also includes two post-doctoral fellowships at Karolinska Institute and McGill University, within the area of signal transduction in breast cancer. Bita also holds an MBA degree in Strategy and Business Valuation from Concordia University John Molson School of Business.

 I’m excited to join the talented life science team at Industrifonden. The Nordic life science landscape is highly innovative and I hope to utilize my scientific expertise and commercial experience to translate strong science into commercially viable products that can improve peoples’ lives, says Bita Sehat.

Industrifonden Life Science is one of the leading venture capital investors in the Nordics, with a focus on pharmaceuticals, medical devices and digital health. Current portfolio companies include Oncopeptides, Calliditas Therapeutics, and AMRA.

Categories: Personalia

Tags:

Mark Voccola joins Ardian as Co-Head of US Infrastructure

Ardian

New York, March 27, 2018: Ardian, a world-leading private investment house, today announces that Mark Voccola will join Ardian New York office in August 2018 as Managing Director of Ardian Infrastructure.

As an industry veteran, Mark has extensive energy sector experience. He will co-lead Ardian’s US infrastructure activities alongside Stefano Mion, Managing Director and Co-Head of Ardian US Infrastructure, and he will be part of Ardian Infrastructure global team now composed of 30 investment professionals.

Mark Voccola will play a leading role shaping Ardian Infrastructure’s vision and strategy in the American continent. When he begins his role in August, he will be responsible for evaluating potential investment opportunities and working alongside Ardian’s industrial long-term partners to identify high-quality American essential infrastructure assets.

Previously, Mark was a Partner in Ares EIF within the Ares Private Equity Group where he was responsible for appraising investment opportunities and monitoring portfolio companies. Prior to joining Ares in 2015, he was a Partner at Energy Investors Funds (EIF).

“Mark’s exceptional credentials and deep energy expertise position him well to lead Ardian Infrastructure’s expansion into the American mid-market alongside Stefano Mion, co-head of Ardian US Infrastructure”, said Mathias Burghardt, Member of the Executive Committee of Ardian and Global Head of Ardian Infrastructure. “His appointment underscores our commitment to the American region, and he will play a critical role in growing our US infrastructure team in the New York office. We welcome him to the team.”

Ardian, already one of the leading European infrastructure manager, has made significant inroads in North America. Mark’s appointment follows Ardian recent announcement that it partnered with Transatlantic Holdings (TPH) to create a renewables platform, Skyline Renewables and acquire Whirlwind, a 60MW windfarm in Texas. Ardian also previously announced its acquisition of LBC Tank Terminals, a global operator of bulk liquid storage facilities with a significant US presence.

ABOUT ARDIAN

Ardian is a world-leading private investment house with assets of US$67bn managed or advised in Europe, North America and Asia. The company is majority-owned by its employees. It keeps entrepreneurship at its heart and focuses on delivering excellent investment performance to its global investor base.

Through its commitment to shared outcomes for all stakeholders, Ardian’s activities fuel individual, corporate and economic growth around the world.

Holding close its core values of excellence, loyalty and entrepreneurship, Ardian maintains a truly global network, with more than 490 employees working from thirteen offices across Europe (Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), North America (New York, San Francisco) and Asia (Beijing, Singapore, Tokyo). It manages funds on behalf of around 700 clients through five pillars of investment expertise: Funds of Funds, Direct Funds, Infrastructure, Real Estate and Private Debt.

www.ardian.com

Categories: Personalia

Tags:

Altor Funds Partner promotions

Altor Equity Partners is happy to announce three Partner promotions; Thomas Kvorning, Andreas Källström Säfweräng and Maria Tallaksen.

Thomas joined Altor in 2007, and currently works on our investments in Haarslev, Hamlet Protein, Norican and Tresu, in addition to contributing to the development and divestment of previous companies such as Sonion and FMD.

Andreas joined Altor in 2006 and works on our investments in CTEK, Infotheek, Meltwater, QMatic and RevolutionRace – and in addition has been working on our recent investments such as O’Learys.

Maria joined Altor in 2007 and currently works on our investments in Enhanced Drilling, FH-gruppen and Spectrum in addition to contributing to the development and divestment of previous investments such as Norsk Gjenvinning and Curato.

For more information, please contact:
Tor Krusell, Head of Communications at Altor, Tel: +46 70 543 87 47

Altor

About Altor
Since inception, the family of Altor funds has raised some EUR 5.8 billion in total commitments. The funds have invested in excess of EUR 3.8 billion in more than 40 companies. The investments have been made in medium sized Nordic companies with the aim to create value through growth initiatives and operational improvements. Among current and past investments are Ålö, Carnegie Investment Bank, Dustin, LRF Konsult and FH-Gruppen. For more information visit www.altor.com.

Categories: Personalia

Nordic Capital continues to strengthen its organisation with appointment of Henrik Johansson as General Counsel

Nordic Capital

Nordic Capital AB today announced that it has appointed Henrik Johansson as its General Counsel, with responsibility for all legal and structure affairs. Henrik is currently a partner at leading Swedish law firm Mannheimer Swartling and will join Nordic Capital later in the year.

Klas Tikkanen, CFO at Nordic Capital AB, commented: “Henrik’s appointment forms part of our strategy to invest in our organisational structure and to develop, broaden and significantly upgrade our in-house legal capabilities. Our Funds have the privilege of working with the best and the brightest advisors, and we felt a need for a senior link into the heart of our commercial work. Mannheimer is a fantastic firm, with whom we have a close and longstanding relationship, and Henrik has personally worked with our team for many years. After an extensive search spanning Stockholm, London and Jersey, it felt very natural to ask him to come and join us in a more permanent capacity.”

Henrik Johansson commented: “Although I feel very fortunate to have spent eleven wonderful years at Mannheimer Swartling, I am at the same time hugely excited about joining Nordic Capital, where I will be able to work with an absolutely world-class team and contribute more fully than I could as a consultant.”

Henrik heads Mannheimer Swartling’s Transaction Structuring Practice, and is a member of the firm’s Mergers & Acquisition, Corporate Taxation, and Private Equity practice groups. He specialises in deal structuring matters, management incentive programmes, co-investments, partner and non-partner structures, fund formation, and similar matters. He works with clients in a wide range of sectors and has a strong focus on private equity. Henrik is ranked as a leading lawyer in Private Equity by Chambers.

Nordic Capital’s team currently comprises 125 people based in Stockholm, London, Jersey, Copenhagen, Frankfurt, Helsinki, Luxembourg and Oslo.

 

Media contacts:

Katarina Janerud, Communications Manager
Advisor to the Nordic Capital Funds
Tel: +46 8 440 50 50
e-mail: katarina.janerud@nordiccapital.com

 

About Nordic Capital

Nordic Capital is a leading private equity investor in the Nordic region with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a proven track record. Core sectors are Healthcare, Technology & Payments, Financial Services, Industrial Goods & Services and Consumer & Retail, and key regions are the Nordics, Northern Europe, and globally for Healthcare. Since inception in 1989, Nordic Capital has invested EUR 12 billion through eight funds. The Nordic Capital Funds are based in Jersey and are advised by advisory companies, which are based in Sweden, Denmark, Finland, Norway, Germany and the UK. For further information about Nordic Capital, please visit www.nordiccapital.com

Categories: Personalia